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There are few clinicopathologic and outcome data on
patients with crescentic lupus nephritis, therefore, we
determined factors of the disease by retrospectively
reviewing the records of 327 patients diagnosed with lupus
nephritis. Of these, 152 cases were regrouped as class IV-G,
including 33 patients with crescentic glomerulonephritis.
Significantly, all patients with crescentic glomerulonephritis
had acute kidney injury as compared with only about a
quarter of the patients without the disease. On pathological
evaluation, activity scores, chronicity indexes, relapse rates,
and the frequency of positive serum anti-neutrophil
cytoplasmic antibody (ANCA) were each significantly higher,
whereas complete remission rates and renal outcomes, over
a mean follow-up of 4 years, were significantly poorer in
patients with crescentic glomerulonephritis. Our study shows
that crescentic glomerulonephritis was not rare in patients
with lupus nephritis and that their long-term outcome was
poor. The precise role of ANCA in the pathologic course of
crescentic lupus nephritis remains to be determined.
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Renal involvement is common in patients with systemic lupus
erythematosus (SLE). The clinical presentation of lupus
nephritis is highly variable, ranging from mild asymptomatic
proteinuria to rapidly progressive glomerulonephritis, and the
occurrence of kidney disease is the most important predictor
of morbidity and mortality in patients with SLE.1
Concerning the classification of lupus nephritis, a new
classification was proposed by the International Society of
Nephrology and Renal Pathology Society (ISN/RPS) in 20032
to rectify some of the problems that have arisen over the
earlier years. Diffuse global lupus nephritis (class IV-G) was
defined as more than 50% of glomeruli display endocapillary
or extracapillary glomerulonephritis. In this class, patients
with crescentic glomerulonephritis, defined as more than
50% of glomeruli, had crescent formation on light micro-
scopy, and always presented with rapidly progressive
glomerulonephritis clinically. However, the ratio of crescentic
glomerulonephritis in patients with lupus nephritis class IV-
G is not clear and the pathogenesis remains inconclusive.
Owing to the relatively limited earlier studies on crescentic
lupus nephritis, the purpose of this study was to assess the
clinical and pathological features, outcome and related
autoantibody profile of crescentic glomerulonephritis in a
cohort of Chinese patients with lupus nephritis.
RESULTS
Among the 327 patients with lupus nephritis in Peking
University First Hospital, 152 cases were reclassified as class
IV-G. In total, 33 of the 152 patients (21.7%) also fulfilled the
diagnosis of crescentic glomerulonephritis.
In patients with crescentic glomerulonephritis, 28 were
female and 5 were male with an average age of 30.9±10.3 (14
to 57) years at presentation. All the patients presented with
rapidly progressive glomerulonephritis clinically. The mean
value of serum creatinine was 3.74±2.68 mg/dl (range
1.7–11.4 mg/dl) on diagnosis.
On renal pathological evaluation of patients with
crescentic glomerulonephritis, the average percentage of
glomeruli with crescents was 66.23±16.76% (range
51.2–95.7%). For constituent of crescents, the average ratio
of cellular, fibro-cellular, and fibrous crescents was
60.8±35.9% (range 0–100%), 29.5±30.6% (range
0–100%), and 9.7±20.9% (range 0–100%), respectively.
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The 33 patients with crescentic glomerulonephritis
received intravenous methylprednisone pulse (500–1000 mg
for three days) therapy. The majority of patients completed
induction treatment with oral prednisone (0.8–1 mg/kg per d
or equivalent for 4–6 weeks and tapered gradually to a
maintenance 5–10 mg/d) (33/33) and monthly intravenous
cyclophosphamide (600–800 mg/month) (30/33) for at least 6
consecutive months. The other three patients received
mycophenolate mofetil. Eight patients achieved complete
remission, 16 had partial remission, and nine failed to
respond. Among the 24 patients with remission, eight
patients reached secondary end point (two with end-stage
renal disease and six with doubling of serum creatinine)
during follow-up. The median time between remission and
end point was 18 months (2–141 months). Among the nine
patients with treatment failure, eight patients reached
secondary end point (five with end-stage renal disease and
three with doubling of serum creatinine). The proportion of
patients reaching renal end point was significantly lower in
remission group than in the non-remission group (8/24 vs 8/9,
P¼ 0.007, Figure 1). In the remission group, nine patients
had a relapse. The proportion of patients reaching renal end
point was significantly lower in the non-relapse group than in
the relapse group (8/9 vs 0/15, Po0.001, Figure 1).
We further compared the clinical and pathological
characteristics of patients with and without crescentic
glomerulonephritis in class IV-G.
Clinical and laboratory parameters
The clinical and laboratory features of patients in the two
groups were listed in Table 1.
There was no significant difference in demographic
features (gender and age) and the time between presenta-
tion/diagnosis of lupus nephritis and biopsy/treatment
between the two groups. In clinical data, there was a
significantly lower proportion of leukocytopenia
(P¼ 0.011), a higher proportion of leukocyturia (non-
infectious) (P¼ 0.021), and a higher proportion of acute
kidney injury (Po0.001) in the crescentic group.
In laboratory findings, there was a significantly lower
hemoglobin level (P¼ 0.015), higher value of serum
creatinine (Po0.001), lower level of creatinine clearance rate
(Po0.001), and lower ratio of positive serum anti-ribonu-
cleoprotein antibody (P¼ 0.044) in patients with crescentic
glomerulonephritis.
Frequency of serum ANCA and anti-glomerular basement
membrane (GBM) antibodies
In total, 10 of the 33 patients (30.3%) in the crescentic
glomerulonephritis group were anti-neutrophil cytoplasmic
antibodies (ANCA)-positive, including nine with p-ANCA
and one with c-ANCA by indirect immunofluorescence and
seven with anti-myeloperoxidase (MPO) antibodies by
enzyme-linked immunosorbent assay (ELISA). Only three
of the 119 patients (2.5%) without crescentic glomerulone-
phritis were ANCA-positive including two with p-ANCA and
one with c-ANCA by indirect immunofluorescence and one
with anti-MPO antibodies by ELISA. The difference in ratio
of positive serum ANCA was significant (Po0.001). One of
the 33 patients in the crescentic glomerulonephritis group
was anti-GBM antibody positive and none of the 119 patients
without crescentic glomerulonephritis was anti-GBM anti-
body positive. However, the difference in ratio of positive
serum anti-GBM antibody was not significant (P¼ 0.217).
Renal histopathological evaluation
The renal histopathological features of patients with and
without crescentic glomerulonephritis were listed in Table 2.
In light microscopic examination, the average number of
biopsied glomeruli between patients with and without
crescentic glomerulonephritis was comparable. According to
the 2003 revised ISN/RPS classification, the lupus nephritis
P=0.007, HR 0.298 (95% CI: 0.108–0.827)
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Figure 1 | Renal outcome in crescentic glomerulonephritis
group. (a) Comparison of renal outcomes between patients with
remission and no remission in crescentic glomerulonephritis
group. (b) Comparison of renal outcomes between patients with
relapse and no relapse in the crescentic glomerulonephritis
group.
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class IV-G was further divided into three subgroups
according to activity and chronicity of the renal lesions, that
is, active lesion only (IV-G(A)), both active and chronic
lesions (IV-G(A/C)), and chronic lesions only (IV-G(C)).
There was a lower ratio of subgroup IV-G(A) and a higher
ratio of subgroup IV-G(A/C) in patients with crescentic
glomerulonephritis than in those without crescentic glomer-
ulonephritis (Po0.001, Po0.001, respectively). In patients
with crescentic glomerulonephritis, there was a significantly
higher score of interstitial inflammation, activity indexes,
tubular atrophy, interstitial fibrosis, and chronicity indexes
(CI) (P¼ 0.002, Po0.001, Po0.001, Po0.001, Po0.001,
respectively) compared with those without crescentic glo-
merulonephritis besides a significant difference in cellular
crescentic score. There was no significant difference in other
indexes between the two groups.
On evaluation of immunofluorescence parameters, there was
no significant difference in the locations of immunoglobulin
deposition between the two groups. However, the average
intensity of IgG, IgA, IgM, C3, C1q, and fibrin was lower in
patients with crescentic glomerulonephritis and the difference in
IgA, IgM and C1q reached statistical significance.
In electron microscopic parameters, there was no
significant difference in the locations of electron dense
deposits between the two groups.
Treatment and outcome
The data of treatment and outcome of patients with and
without crescentic glomerulonephritis were shown in
Table 3.
There was no significant difference in treatment algorithm
between the two groups, except that there was a significantly
Table 1 | Comparisons of clinical data and laboratory data between patients with lupus nephritis class IV-G with and without
crescentic glomerulonephritis
Crescentic
glomerulonephritis
Non-crescentic
glomerulonephritis P-value
Clinical data
Number of patients 33 119
Gender (male/female) 5/28 21/98 0.736
Age (mean±s.d.) (years) 30.9±10.3 31.5±10.8 0.774
The time between presentation/diagnosis of lupus
nephritis and biopsy/treatment (mean±s.d. and range) (months)
16.8±28.8 (0.5–120) 14.2±23.4 (1–110) 0.653
Hypertension (blood pressureX140/90 mm Hg), n (%) 21 (63.6) 68 (57.1) 0.503
Systolic blood pressure (mean and range) (mmHg) 140 (110–160) 140 (110–150) 0.768
Diastolic blood pressure (mean and range) (mmHg) 80 (80–90) 80 (70–90) 0.912
Fever, n (non-infectious) (%) 8 (24.2) 31 (26.1) 0.833
Malar rash, n (%) 19 (57.6) 57 (47.9) 0.432
Photosensitivity, n (%) 6 (18.2) 20 (16.8) 0.8
Oral ulcer, n (%) 8 (24.2) 32 (26.9) 0.827
Alopecia, n (%) 10 (30.3) 34 (28.6) 0.831
Arthralgia, n (%) 21 (63.6) 54 (45.4) 0.077
Serositis, n (%) 7 (21.2) 22 (18.5) 0.803
Neurological disorder, n (%) 4 (12.1) 13 (10.9) 0.765
Anemia, n (%) 32 (97) 103 (86.6) 0.122
Leukocytopenia, n (%) 11 (33.3) 70 (58.8) 0.011
Thrombocytopenia, n (%) 11 (33.3) 46 (38.7) 0.686
Hematuria, n (%) 33 (100) 111 (93.3) 0.202
Leukocyturia (non-infection), n (%) 28 (84.8) 76 (63.9) 0.021
Nephrotic syndrome, n (%) 25(75.8) 84 (70.6) 0.665
Acute kidney injury, n (%) 33 (100) 32 (26.9) o0.001
SLEDAI (mean±s.d.) 19.85±5.35 19.35±5.31 0.637
Laboratory data
Number of patients 33 119
Hemoglobin (mean±s.d.) (g/l) 84.61±19.46 95.03±21.97 0.015
Urine protein (mean±s.d.) (g/24 h) 6.25±3.54 5.85±3.89 0.598
Serum creatinine (mean±s.d.) (mg/dl) 3.74±2.68 1.61±1.57 o0.001
Creatinine clearance rate (mean±s.d.) (ml/min) 25.83±26.28 64.52±31.26 o0.001
Serum albumin (mean±s.d.) (g/dl) 2.54±0.67 2.71±0.42 0.563
Positive ANA, n (%) 33 (100) 119 (100) 1.0
Positive anti-ds-DNA, n (%) 25 (75.8) 91 (76.5) 1.0
Positive anti-Sm, n (%) 5 (15.2) 27 (22.7) 0.471
Positive anti-SSA, n (%) 14 (42.4) 53 (44.5) 0.846
Positive anti-SSB, n (%) 6 (18.2) 15 (12.6) 0.403
Positive anti-RNP, n (%) 4 (12.1) 36 (30.3) 0.044
Anti-cardiolipin antibody, n (%) 1/20 (5) 7/78 (9) 1.0
C3 (mean±s.d.) (g/l) 0.38±0.16 0.38±0.16 1.0
ANA, anti-nuclear antibodies; RNP, ribonucleoprotein; SLEDAI, systemic lupus erythematosus disease activity index; SSA, Sjo¨gren’s syndrome A antigen; SSB, Sjo¨gren’s
syndrome B antigen.
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higher number of patients using intravenous methylprednisone
pulse in the crescentic glomerulonephritis group (Po0.001).
The proportion of complete remission was significantly lower
and the proportions of partial remission and treatment
failure were significantly higher in the crescentic group
(Po0.001, P¼ 0.01, Po0.001, respectively). The cumulative
incidences of the first complete remission, partial remission,
and total remission were shown in Figure 2. At the time of
remission, there was a significantly higher level of proteinuria
(Po0.001), a higher value of serum creatinine (Po0.001),
and a lower level of creatinine clearance rate (Po0.001) in
the crescentic group.
During maintenance therapy, nine patients in the
crescentic group (eight with nephritic relapse and one with
proteinuric relapse) and 17 patients in the non-crescentic
group (nine with nephritic relapse and eight with proteinuric
relapse) had a relapse. The relapse rate was significantly
higher in the crescentic group (37.5% vs 15.2%, P¼ 0.012,
Figure 3). All of the relapses occurred on maintenance
therapy. All the nine patients in the crescentic group were
with cyclophosphamide compared with 11 patients with
cyclophosphamide, one with azathioprine, and five with
leflunomide in non-crescentic group. After relapses, all of the
patients increased the dosage of corticosteroids, 12 patients
reused monthly pulses of cyclophosphamide, and three
patients changed to mycophenolate mofetil. Five and 12
patients achieved remission again, four and five patients
presented with treatment failure in crescentic and non-
crescentic groups, respectively.
Most patients in the two groups used ACE (angiotensin-
converting enzyme) inhibitor and blood pressure was
controlled well, and there was no significant difference
between the two groups. Regarding ANCA, seven (both p-
ANCA positive) of the 10 patients with positive ANCA by
indirect immunofluorescence in the crescentic group re-
mained positive and the other three patients turned negative.
The titers of anti-MPO antibodies of the seven positive
patients in the crescentic group decreased during follow-up,
Table 2 | Comparison of renal pathological data between patients with lupus nephritis class IV-G with and without crescentic
glomerulonephritis: light microscopy; direct immunofluorescence and electron microscopy
Crescentic
glomerulonephritis
Non-crescentic
glomerulonephritis P-value
Light microscopy
Number of biopsies 33 119
Number of glomeruli (mean±s.d.) 24.1±8.5 25.4±11.9 0.167
% of cases with sub-class A 42.4 79 o0.001
% of cases with sub-class A/C 54.5 21 o0.001
% of cases with sub-class C 3.1 0 0.217
% of cases with fibrinoid necrosis 3 (1/33) 5 (6/119) 1.0
% sclerotic glomeruli (median and range) 0, 0–27 0, 0–60 0.174
AI score (mean±s.d.) 13.48±3.09 10.22±3.09 o0.001
Endocapillary hypercellualrity (mean±s.d.) 2.88±0.49 2.93±0.28 0.416
Cellular crescents (mean±s.d.) 4.82±1.79 1.55±1.46 o0.001
Karyorrhexis/fibrinoid necrosis (mean±s.d.) 1.27±1.10 1.45±1.18 0.431
Subendothelial hyaline deposits (mean±s.d.) 1.27±0.91 1.66±1.04 0.052
Interstitial inflammation (mean±s.d.) 1.88±0.93 1.40±0.71 0.002
Glomerular leukocyte infiltration (mean±s.d.) 1.12±0.82 1.41±1.47 0.278
CI score (mean±s.d.) 4.85±2.17 2.86±1.77 o0.001
Glomerular sclerosis (mean±s.d.) 0.61±0.70 0.39±0.60 0.087
Fibrous crescents (mean±s.d.) 0.67±0.92 0.12±0.35 o0.001
Tubular atrophy (mean±s.d.) 1.82±0.85 1.24±0.66 o0.001
Interstitial fibrosis (mean±s.d.) 1.76±0.83 1.12±0.69 o0.001
Direct immunofluorescence and electron microscopy
Number of biopsies 33 119
Immunofluorescence parameters
% of cases with capillary loop deposition 97 100 0.217
% of cases with mesangial deposition 69.7 81.5 0.153
IgG (mean±s.d.) 1.82±0.98 2.14±0.91 0.075
IgA (mean±s.d.) 1.52±1.06 1.95±0.87 0.017
IgM (mean±s.d.) 1.27±0.98 1.66±0.95 0.039
C3 (mean±s.d.) 2.42±1.00 2.67±0.71 0.11
C1q (mean±s.d.) 1.76±0.97 2.2±0.83 0.01
Fibrin (mean±s.d.) 0.55±0.75 0.73±0.82 0.244
Electron microscopy parameters
% of cases with subendothelial deposition 63.6 70.6 0.524
% of cases with subepithelial deposition 69.7 71.4 0.831
% of cases with mesangial deposition 78.8 76.5 1.0
% of cases with intramembranous deposition 33.3 25.2 0.379
A, active lesions; AI, activity indexes; C, chronic lesions; CI, chronicity indexes.
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but only two patients turned negative. In the non-crescentic
group, p-ANCA in one of the three patients turned negative
and the other two patients remained positive by indirect
immunofluorescence. The titer of anti-MPO antibodies of
one patient decreased and remained positive in the non-
crescentic group.
Repeated kidney biopsy was carried out in 10 patients,
including one in the crescentic group and the other nine in
the non-crescentic group (details in Table 4).
During follow-up (average for nearly 4 years), there was
no significant difference between the two groups regarding
long-term survival. In the crescentic group, all the patients
survived and only one patient died of severe infection in
those without crescentic glomerulonephritis. Regarding long-
term renal outcome, patients with crescentic glomerulone-
phritis had a significantly poorer renal outcome (Po0.001,
Figure 4). Nine (27.3%) patients had a doubling of serum
creatinine and seven (21.2%) reached end stage renal disease
in crescentic group. In patients without crescentic glomer-
ulonephritis, nine patients (7.6%) had a doubling of serum
creatinine and four (3.4%) reached end-stage renal disease.
As patients in the crescentic group clearly had a worse serum
creatinine and creatinine clearance at baseline with higher CI
in the biopsy, we further carried out an adjusted proportional
hazard analysis accounting for those baseline differences and
confirmed that patients with crescentic glomerulonephritis
had a significantly poorer renal outcome (Table 5).
We further compared the value of remission and relapse
(Figure 4) determining the overall renal survival between the
crescentic and non-crescentic groups. We found that both
remission and relapse could affect renal survival besides the
pathological difference. As there was no secondary end point
occurring in patients without relapse in both two groups, the
similar analysis was not done.
DISCUSSION
Renal involvement is common in SLE and there are a number
of different pathological phenotypes of lupus nephritis.
Although crescent formation is common in lupus nephritis
especially in the background of proliferative glomerular
lesions, the ratio of ‘true’ crescentic glomerulonephritis in
lupus nephritis is not clear and the pathogenesis remains
inconclusive.
In our study, we found that crescentic glomerulonephritis
was not rare in lupus nephritis, which accounted for 10.1% of
total biopsy-proven lupus nephritis and 21.7% of lupus
Table 3 | Comparison of treatments between patients with lupus nephritis class IV-G with and without crescentic
glomerulonephritis; comparison of renal outcomes between patients with lupus nephritis class IV-G with and without
crescentic glomerulonephritis
Crescentic glomerulonephritis
n=33 Number of patients (%)
Non-crescentic glomerulonephritis
n=119 Number of patients (%) P-value
Comparison of treatments
Induction treatment
Methylprednisone impulse 33 (100) 56 (47.1) o0.001
Oral prednisone 33 (100) 119 (100) 1
Cyclophosphamide i.v. 30 (90.9) 111 (93.3) 0.705
Mycophenolate mofetil 3 (9.1) 8 (6.7) 0.705
Maintenance treatment
Oral prednisone 33 (100) 119 (100) 1.0
Cyclophosphamide i.v. 31 (94) 94 (79) 0.069
Azathioprine 0 (0) 3 (2.5) 1.0
Mycophenolate mofetil 1 (3) 7 (5.9) 1.0
Leflunomide 1 (3) 15 (12.6) 0.196
Treatment response
Complete remission 8 (24.2) 82 (68.9) o0.001
Partial remission 16 (48.5) 30 (25.2) 0.01
Treatment failure 9 (27.3) 7 (5.9) o0.001
The time between initiation of treatment and final remission
(mean±s.d.) (months)
7.17±1.86 6.62±1.78 0.174
Urine protein at remission (mean±s.d.) (g/24 h) 1.21±0.36 0.52±0.18 o0.001
Serum creatinine at remission (mean±s.d.) (mg/dl) 1.65±0.86 0.82±0.35 o0.001
Creatinine clearance rate at remission (mean±s.d.) (ml/min) 45.77±12.34 73.25±11.64 o0.001
Comparison of renal outcomes
Duration of follow-up (mean±s.d.) (months) 47.4±48.3 54.3±54.8 0.523
Cumulative dose of cyclophosphamide (mean±s.d.) (g) 7.35±2.64 7.96±3.79 0.453
Use of ACE inhibitor 18 (55) 75 (63) 0.376
Use of benazepril 13 (13/18,72.2%) 62 (62/75,82.7%) 0.314
Use of fosinopril 5 (5/18,27.8%) 13 (13/75,17.3%) 0.314
Control of blood pressurep130/80 mm Hg 26 (79) 99 (83) 0.558
Relapse rate 9 (9/24,37.5%) 17 (17/112, 15.2%) 0.012
The time between remission to relapse (mean and range) (months) 17 (2–141) 51 (14–152) 0.112
ACE, angiotensin-converting enzyme; i.v., intravenous.
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nephritis class IV-G. In the literature, Sumethkul V et al.3
showed that lupus nephritis with crescentic glomerulone-
phritis accounted for 51.6% (32/62) of all patients with
biopsy-proven various crescentic glomerulonephritis. There-
fore, lupus nephritis with crescentic glomerulonephritis
should be paid more attention.
In comparison with lupus nephritis class IV-G without
crescentic glomerulonephritis, it was not surprising that
patients with crescentic glomerulonephritis had a signifi-
cantly higher proportion of acute kidney injury and a lower
hemoglobin level because of the presence of rapidly
progressive glomerulonephritis clinically. We also found a
lower proportion of positive serum anti-ribonucleoprotein
antibodies in the crescentic group. Although the difference is
marginal, a further study with a larger sample size is needed
to clarify the clinical significance.
On histopathological evaluation, besides the difference in
ratio of crescent formation, we found that there were
significantly higher scores of interstitial inflammation,
activity indexes, tubular atrophy, interstitial fibrosis, and CI
in patients with crescentic glomerulonephritis than in
those without crescentic glomerulonephritis. These results
suggested that both acute and chronic lesions were
prominent in patients with crescentic glomerulonephritis.
More interestingly, we found that the average intensity of
IgG, IgA, IgM, C3, C1q, and fibrin were lower in the
crescentic group by immunofluorescence and the average
intensity of IgG, IgA, and IgM was o2þ . Combined with
the immunofluorescence presentation and a higher ratio of
the subclass IV-G(A/C) by light microscopy, crescentic
glomerulonephritis in lupus nephritis seemed more like
‘pauci-immune’ crescentic glomerulonephritis because of
ANCA-associated vasculitis. Therefore, we further detected
serum ANCA and anti-GBM antibodies in all of the patients
with lupus nephritis class IV-G. The result was so striking
that nearly 1/3 of patients with crescentic glomerulonephritis
were ANCA-positive, compared with only 2.5% of patients
without crescentic glomerulonephritis. We used Hep-2 cell
P=0.001, HR 3.785 (95% CI: 1.822–7.861) P=0.59, HR 0.858 (95% CI: 0.464–1.586)
P=0.009, HR 1.856 (95% CI: 1.189–2.897)
Median time (interquartiles months): 8 (6.9)
Median time (interquartiles months): 6 (6.7)
Median time (interquartiles months): 7 (6.9)
Median time (interquartiles months): 8 (4.9)
Median time (interquartiles months): 6 (5.6)
Median time (interquartiles months): 6 (4.8)
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Figure 2 | The cumulative incidences of the first complete remission, partial remission, and total remission between patients with
lupus nephritis class IV-G with and without crescentic glomerulonephritis. (a) Complete remission. (b) Partial remission. (c) Total
remission. CrGN, crescentic glomerulonephritis group; Non-CrGN, non-crescentic glomerulonephritis group.
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and paraformaldehyde-fixed neutrophils to allow for the
distinction between anti-nuclear antibodies and p-ANCA.
For further detailed analysis of the 10 patients with positive
ANCA in patients with crescentic glomerulonephritis, we
could not find a history of taking special medications such as
hydralazine, propylthiouracil, etc. Therefore, drug-induced
SLE with multi-autoantibodies including ANCA was unlikely.
More importantly, we found that 8 out of the 10 patients
presented with ‘pauci immune’ by immunofluorescence and
no significant subendothelial deposits by electron micro-
scopy. Therefore, they might be diagnosed simultaneously as
renal involvement of ANCA-associated vasculitis. However,
in this study, only a few patients had necrosis and there was
no difference between the two groups, which is less consistent
with vasculitis. The explanation was the following: first, the
fibrinoid necrotic lesions could be found in both lupus
nephritis and ANCA-associated vasculitis, but were not
diffuse; second, owing to the focal and segmental nature,
the percentage of glomeruli with fibrinoid necrosis was
dependent on the number of sections of renal tissue: the
higher the number of sections, the higher the percentage of
necrosis; third, the sample size, especially of patients with
crescents was small. These might be attributed to the
comparable percentage of fibrinoid necrosis between the
two groups in our study. We also noticed a lower proportion
of leukocytopenia in the crescentic group, which might be
explained by the existence of leukocytosis in patients with
ANCA-associated vasculitis, but this needs further study.
It is known that 15–20% of patients with SLE have
detectable serum ANCA.4 Indeed, isolated cases have been
reported in which ANCA seems clearly to be implicated as a
major pathogenetic factor and might play a role in the
development of necrotizing vasculitis and crescent formation
in lupus nephritis.5–7 Some authors had found a correlation
between the presence of serum ANCA and the formation of
crescents in patients with lupus nephritis,8 an association
between p-ANCA, such as anti-cathepsin G antibodies, and
the development of lupus nephritis.9,10 Although several
other studies have failed to find a correlation between ANCA
with lupus nephritis,11–14 most authors have indicated that
ANCA seropositivity was commonly encountered in patients
with SLE, especially those with the disproportionate
necrotizing and crescentic features in lupus nephritis. It has
been suggested that the occurrence of positive ANCA in
patients with SLE might indicate overlaps of SLE and ANCA-
associated vasculitis.6,7 In this study, we show the high
prevalence of ANCA in sera from patients with both lupus
nephritis class IV-G and crescentic glomerulonephritis. The
phenomenon might be explained by the following two
reasons: first, there might indeed exist overlapping of lupus
nephritis and ANCA-associated vasculitis in these patients as
reported earlier;15–17 second, ANCA, as one of many possible
autoantibodies in SLE, might be implicated as a pathogenetic
factor for the development of crescentic glomerulonephritis.
Nasr16 recently proposed that one of the two conditions
(ANCA and lupus nephritis) may be creating fertile
conditions for the second to develop. It was suggested
that lupus nephritis might facilitate the process of MPO
Table 4 | Profile of patients with lupus nephritis class IV-G who underwent repeat biopsies
Patient Interval between
Renal pathology type Activity indexes Chronicity indexes
No. Reason for rebiopsy biopsies (months) Pre Post Pre Post Pre Post
1 Relapse 7 IV IV 11 15 3 3
2 Relapse 15 IV IV 11 7 9 9
3 Relapse 38 IV V+III 5 6 0 1
4 Relapse 35 IV IV+V 7 9 2 2
5 Relapse 10 IV IV 12 14 3 3
6 Re-evaluation 12 IV III+V 13 3 1 1
7 Re-evaluation 9 IV III+V 12 2 2 1
8 Relapse 39 IV IV 8 9 0 2
9 Relapse 11 IV IV+V 7 8 2 2
10 Relapse 18 IV IV 6 9 2 3
Patient 1 was in crescentic group and patients 2B10 were in non-crescentic group.
P =0.004, HR 0.319 (95% CI: 0.141–0.724)
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Figure 3 | Comparison of renal relapse rates between patients
with lupus nephritis class IV-G with and without crescentic
glomerulonephritis. CrGN, crescentic glomerulonephritis group;
Non-CrGN, non-crescentic glomerulonephritis group.
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autoantibody formation by promoting neutrophil degranula-
tion and priming neutrophils to increase surface expression
of MPO.
Besides ANCA, other participants of crescent formation,
such as coagulation factors, particularly fibrin, tissue factor,
and several different proliferating cell types, including the
macrophage, the parietal glomerular epithelial cell, podo-
cytes, and the interstitial fibroblast, should be further studied
in lupus nephritis.18–27
Although there are no well-established guidelines for the
treatment of crescentic glomerulonephritis in patients with
lupus nephritis, most authors including us suggested
intensive immunosuppressive therapy on the therapeutic
basis of proliferative lupus nephritis.3,16 Sumethkul V et al. 3
showed that therapy with intravenous cyclophosphamide was
not necessarily associated with good outcome and that daily
oral cytotoxic drugs should be considered as a more
reasonable alternative therapy. A recent study from China
even showed that higher complete remission ratio and lower
relapse ratio were observed in the mycophenolate mofetil
group than in the cyclophosphamide group for the induction
therapy in patients with crescentic lupus nephritis.28
Though our lupus nephritis class IV-G patients with
crescentic glomerulonephritis received intravenous methyl-
prednisone pulse therapy, patients with crescentic glomer-
ulonephritis had a significantly poorer renal outcome
compared with those without crescentic glomerulonephritis
after a 4-year follow-up. This might be associated with more
severe renal injury and a higher CI score in renal
histopathology of patients with crescentic glomerulonephri-
tis. More importantly, the rate of complete remission was
significantly lower, the rate of treatment failure was
significantly higher, and relapses occurred significantly more
often in crescentic group. At the time of remission, there still
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Figure 4 | Comparison of renal outcomes between patients with and without crescentic glomerulonephritis. (a) Comparison of
renal outcomes between patients with lupus nephritis class IV-G with and without crescentic glomerulonephritis. (b) Comparison of renal
outcome between patients with remission and no remission in lupus nephritis class IV-G with and the without crescentic glomerulonephritis
group. (c) Comparison of renal outcomes between patients with relapse in lupus nephritis class IV-G with and without the crescentic
glomerulonephritis group. CrGN, crescentic glomerulonephritis group; Non-CrGN, non-crescentic glomerulonephritis group.
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was a significantly higher level of proteinuria, a higher value
of serum creatinine, and a lower level of creatinine clearance
rate in the crescentic group. These are well known risk factors
for deterioration of renal function.29–30 Even in patients with
crescentic lupus nephritis, those with a higher remission rate
and/or lower relapse rate could have a better renal outcome.
In conclusion, crescentic glomerulonephritis was not rare
in patients with lupus nephritis. ANCA might play a role in
crescent formation. Although intensive immunosuppressive
therapy could achieve clinical remission, their long-term
renal outcome was poor.
MATERIALS AND METHODS
Patients
The renal histopathological data of 327 patients with renal biopsy-
proven lupus nephritis, diagnosed between January 2000 and July
2008 in Peking University First Hospital, were reviewed and
reclassified according to the 2003 revised classification of ISN/
RPS2 by two experienced pathologists. Patients with diffuse global
proliferative lupus nephritis (class IV-G), defined as more than 50%
of glomeruli displaying endocapillary or extracapillary glomerulo-
nephritis, were recruited. Only biopsy specimens with more than 10
glomeruli were included in this study. Crescentic glomerulonephritis
was defined as over half of the total glomeruli affected by large
crescents (the crescent takes up over half space in Bowman’s capsule)
by light microscope,31 which should be included in class IV-G lupus
nephritis.
The patients fulfilled the 1997 American College of Rheumato-
logy revised criteria for SLE.32 The disease activity was assessed by
the SLE Disease Activity Index (SLEDAI).33,34
Renal histopathology
The renal biopsy specimens were examined under light microscopy,
direct immunofluorescence and electron microscopy techniques.
Light microscopy examination. Renal biopsy specimens were
fixed in 4.5% buffered formaldehyde for light microscopy.
Consecutive serial 3-mm sections were used for histological staining.
Stains employed included hematoxylin and eosin, periodic acid-
Schiff, silver methenamine, and Masson’s trichrome. Differences in
scoring between the two pathologists were resolved by re-reviewing
the biopsies and coming to a consensus. Pathological parameters
such as activity indexes and CI were approached by renal
pathologists using a modification of an earlier reported system
involving semi-quantitative scoring of specific biopsy features.35,36
Direct immunofluorescence examination. The immuno-
fluorescence for deposition of immunoglobulin IgG, IgA, IgM, C3,
C1q, and fibrin deposits was semi-quantitatively graded from 0 to
4þ according to the intensity of fluorescence. Intensity of staining
was scored as negative (0), mild (1þ ), moderate (2þ ), strong
(3þ ), or very strong (4þ ).37,38
Electron microscopy examination. Renal biopsy specimens
were fixed in 2.5% paraformaldehyde for electron microscopy. After
being embedded in epon, ultrathin sections were mounted on metal
grids and stained with uranyl acetate before being viewed in a
transmission electron microscope (JEM-1230; JEOL, Tokyo, Japan).
For this study, specimens were examined with an emphasis on
subendothelial, subepithelial, mesangial, and intramembranous
electron-dense deposits.
Clinical evaluation
The detailed clinical data of patients were retrospectively analyzed.
The remission of lupus nephritis includes complete remission
and partial remission.39–42 Complete remission was defined as
urinary protein excretion of o0.3 g/day, with normal urinary
sediments (RBCo3/HP, WBCo5/HP), serum albumin, and renal
function. Partial remission was defined as the presence of any one of
the following features: decrease of serum creatinine to below
130 mmol/l for patients with a baseline serum creatinineX130 mmol/
l, but p260 mmol/l; decrease of serum creatinine by 450% for
patients with a baseline serum creatinine 4260mmol/l; decrease of
urinary protein excretion by 450%, and below 3.0 g/24 h, with a
serum albumin X30g/l and stable renal function. Treatment failure
was defined as any of the following: failure of the serum creatinine
level to decrease to below 130mmol/l for patients with a baseline
serum creatinine X130 mmol/l, but p260 mmol/l; failure of the
serum creatinine to improve by 50% for patients with a baseline
serum creatinine 4260mmol/l; urinary protein excretion 43.0 g/
24 h; failure of urinary protein excretion to improve by 50%; serum
albumin o30 g/l.
A relapse was defined as (1) nephritic relapse: a recent increase of
serum creatinine by 450% with active urinary sediments and (2)
proteinuric relapse: development of either a nephrotic syndrome
(proteinuria 43.5 g/day and serum albumin o30 g/l) or proteinuria
41.5 g/day without other causes, in an earlier nonproteinuric patient.30,43
The patients were followed up in an outpatient clinic specified
for patients with lupus nephritis. The primary end point was defined
as death and the secondary end point was defined as end-stage renal
disease or the doubling of serum creatinine.
Informed consent was obtained for blood sampling and renal
biopsy from each patient. The research was in compliance of the
Declaration of Helsinki principles.
Table 5 | Comparison of renal outcomes between patients
with lupus nephritis class IV-G with and without crescentic
glomerulonephritis (unadjusted and adjusted baseline
indexes)
Unadjusted Cox hazard analysis
HR (95%CI) P-value
Group o0.001
Crescentic 1
Non-crescentic 0.177 (0.083–0.376)
Adjusted chronicity indexes and serum creatinine
Cox hazard analysis
Group 0.022
Crescentic 1
Non-crescentic 0.387(0.172–0.870)
Chronicity indexes 1.190(0.988–1.434) 0.066
Serum creatinine 0.006
p1.5 mg/dl 1
41.5 mg/dl 8.678(1.867–30.327)
Adjusted chronicity indexes and creatinine
clearance rate Cox hazard analysis
Group 0.004
Crescentic 1
Non-crescentic 0.301 (0.134–0.677)
Chronicity indexes 1.364 (1.134–1.641) 0.001
Creatinine clearance rate 0.697
X80 ml/min 1
o80 ml/min 1.369 (0.281–6.674)
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Blood samples
For detection of ANCA and anti-GBM antibodies, sera were
obtained from peripheral blood at the same day of renal biopsy.
All sera were stored at 701C until use.
Detection of ANCA and anti-GBM antibodies in sera from
patients with lupus nephritis class IV-G
ANCA tests were carried out by both indirect immunofluorescence
assay and antigen-specific ELISA. Standard indirect immunofluor-
escence assay was carried out using pre-cooled ethanol-fixed normal
peripheral neutrophils as substrate according to the manufacturer
(Euroimmun, Lu¨beck, Germany). The use of Hep-2 cell and
paraformaldehyde-fixed neutrophils may allow the distinction
between anti-nuclear antibodies and p-ANCA. In antigen-specific
ELISA, highly purified human neutrophil MPO, purified as reported
earlier,44 was used as a solid-phase ligand to detect MPO–ANCA,
and an earlier described sandwich-ELISA was used to detect PR3-
ANCA.44 Serum anti-GBM antibodies were detected by ELISA using
a highly purified bovine non-collagenous NC1 domain of a chains
of type IV collagen (a(IV) NC1) as solid-phase ligand as reported
earlier.45
Statistical analysis
For statistical analysis, statistical software SPSS 13.0. (SPSS, Chicago,
IL, USA) was used. Quantitative data were expressed as mean±s.d.,
and median with range (minimum, maximum). For a comparison
of the clinical and pathological features of patients, Student’s t-test,
one-way analysis of variance, and w2-test were used. Kaplan–Meier
curves were used to analyze patients’ prognosis. Survival analysis
was carried out using the log-rank test and the Cox regression
model. Results were expressed as hazard ratio with 95% confidence
intervals. Statistical significance was considered as Po0.05.
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